Analysis of Strategy for Extending Patent Protection of Rucaparib

As a knowledge-intensive and promising strategic emerging industry, the biomedical industry has high entry thresholds, large R&D investment, long cycle, high risk and high return. In all technical fields, the biomedical industry has the highest dependence on intellectual property rights, and the protection of pharmaceutical intellectual property rights by domestic and foreign biomedical enterprises also runs through the whole process of drug research and development. Extending the patent protection period of drugs as well as forming and strengthening patent fortresses requires a patent network that surrounds drugs to maximize the value of intellectual property protection, which is also the focus of every pharmaceutical company with patent rights. By analyzing the patent portfolio of Clovis Oncology Company in the United States on Rucaparib and the patent portfolio of other companies or applicants on Rucaparib, we can have a clearer understanding of the strategy of extending the patent protection period of a new drug product.

Patent Protection in China

The nucleus of the patentsystem is to protect patent rights,i.e.,to protect the legitimate rightsof patentees and Interested parties.Since China’s first patent law cameinto force in April 1985,the ChinesePatent Office and local patentadministrative organs havecontinuously attached primeimportance to the protection ofpatent rights,and gratifying resultshave been achieved in this field.

Research on the Status of Patent Protection of Prostaglandin Analogues for Glaucoma in China

Objective To study and analyze the status of patent protection of prostaglandin analogues for glaucoma in China.Methods Patent literatures published up to April 7,2020 were retrieved by the keywords“PG”and“prostaglandin”on such patent information service platforms as SIPO,SooPat,and IncoPat.And then they were statistically analyzed by qualitative and quantitative means.Results and Conclusion A total of 300 patent literature related to prostaglandin analogues for glaucoma were obtained,and most of them were invention patents,including patents for composition and dosage form,indications and uses,related synthesis,the compound,and composition preparations.Prostaglandin analogues play an important role in the treatment of glaucoma.At present,China has a large number of patents applications,and the patent protection covers a wide range of technical fields,but the number of patents with valid legal status is relatively small.Therefore,China’s pharmaceutical enterprises and R&D institutions have more options in topic selection and project approval and patent protection strategies.

Patent Protection in Daily Chemical Industry in China

In this paper, the present patent situation of the daily chemical industry was analyzed. The development trends of China patent protection in daily chemical industry were analyzed including patent application trend, patent type and applicant type. As a leading enterprise, the patent protection situation of P＆G was analyzed, which is significant for domestic enterprises. Finally, suggestions for China daily chemical industry were given according to the analysis results and experiences of the leading company from the perspective of patent protection.

Managing Two-Echelon Remanufacturing Under Patent Protection

We propose a two-echelon remanufacturing model in the context of two periods in which the factor of patent protection of the original manufacturer is considered.Through the analysis of the Stackelberg game among the supplier,the original manufacturer and the remanufacturer we obtain the equilibrium solutions of the unit patent licensing fee of the original manufacturer,the recycling effort degree of the remanufacturer,the wholesale price of new and remanufactured core components and the retail price of new and remanufactured products in the second period which are all dependent on the retail price of new products in the first period in cases with patent protection and without patent protection.In the numerical study we analyze the impacts of the remanufacturing rate of used products and the retail price of new products in the first period on the equilibrium results of the second period,and make a comparison between the case with patent protection and the case without patent protection.

Comparative Study on the Domestic and Abroad Patent Application about Liquid Laundry

In this paper, a comparison on the domestic and abroad patent application about liquid laundry was provided which related to the patent application number and the change trend, the patent protection subject, patent strategy, and the patent application writing style. Especially, the applications from the domestic and abroad important applicants were analyzed. Based on the analysis mentioned above, this paper also provided the reference and recommendations from the patent view for practitioners of technology field.

专利诉讼中存在的问题及对策

专利诉讼是专利保护制度的重要组成部分。在我国目前的专利诉讼制度中还存在着若干不完善的地方。本文就专利诉讼中有关当事人的确定、证明责任的分配和地方保护主义对专利诉讼的干扰的问题进行分析 。

“337调查”侵权判定影响因素的实证研究——来自美国ITC的证据

]利用2005—2015年美国"337调查"涉案的42个国家面板数据,实证研究"337调查"案件侵权判定的影响因素。研究发现,各国当年拥有的PCT专利、美国授权的专利数、汇率以及美国民主党执政对美国"337调查"侵权率有显著影响。美元贬值、民主党执政将减少美国"337调查"案件判定的侵权率;一国拥有专利数量的增加,反而会导致美国判定更多案件侵权。这一结果表明美国对本国产业的保护意图更加强烈,"337调查"更多意义上是一种不公平的知识产权壁垒。

知识产权型新技术贸易壁垒对策研究

在知识经济深度发展背景下,传统的技术贸易壁垒正在逐渐向知识产权与技术标准协同型新技术贸易壁垒演变。知识产权的过度滥用行为导致中国出口企业产品被海关扣押、被迫支付巨额专利费、企业陷入亏损以及企业利润下降。针对美国"337调查"、发达国家专利流氓以及美欧专利联盟,分别实施不同的应对之策,遏制新型贸易保护主义,增强企业、产业和国家的核心竞争力。

行政边界与专利知识传播

构建全国统一大市场是党的二十大报告中的重要任务,其关键在于破除地方保护和区域壁垒,促进各类生产要素的自由流动。本文利用2002~2015年中国近750万条专利引用数据,考察行政边界是否对专利知识的跨区域传播产生影响。研究发现,与省内专利引用相比,省际专利引用的概率下降约2.4%,专利引用量下降约4.4%。机制分析发现,知识产权司法地方保护削弱了企业间研发合作以及异地投资所产生的知识传播效应;地方政府主要通过本地国企来实现知识传播的行政分割,对本地央企专利知识的对外传播没有显著影响。高技术产值占比越大的城市在专利知识传播过程中呈现更强的边界效应。进一步研究发现:跨区域专利知识传播受阻将导致地区创新产出水平下降约15.8%;推动实现更高质量的区域经济一体化能够有效促进专利知识的跨区域流动。